News Column

Erytech Selects 2 Independent Board Members

June 23, 2014

Erytech Pharma reported that it has appointed Dr. Martine George and Hilde Windels as new independent members to its board of directors.

According to a release from the company, Dr. George is an experienced US based clinical research, medical affairs and regulatory affairs executive, both in large and small oncology companies.

Erytech said that until recently Dr. George was Vice President Global Medical Affairs, Oncology at Pfizer in New York. Her previous functions before Pfizer included Chief Medical Officer at GPC Biotech in Princeton and Head of oncology at Johnson & Johnson in New Jersey.

"We are delighted and proud to have these seasoned professionals joining our Board of Directors. Their respective experiences in oncology drug development and financial affairs will be of great value at this important time for the company. With Phase III data for our lead product expected in a few months, and three other clinical programs ongoing, in Europe and the USA, ERYTECH making its steps to build a strategic value in orphan oncology," said Gil Beyen, Chairman and CEO of Erytech.

Erytech is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

More information:

www.erytech.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Health & Beauty Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters